N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). - sprookjes - yvandenbroek - TriplyDB

N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').

N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').

http://www.wikidata.org/entity/Q34360861

about

MDMA for the treatment of mood disorder: all talk no substance?Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine mCPP: an undesired addition to the ecstasy market Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs.Multiorgan failure from 1-benzylpiperazine ingestion--legal high or lethal high?The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine.Prevalence of new psychoactive substances: A retrospective study in hair.Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department.3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Benzylpiperazine: a drug of abuse?Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats.Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.Toxicity from the recreational use of 1-benzylpiperazine.Contributions of serotonin in addiction vulnerability.MDMA-like behavioral effects of N-substituted piperazines in the mouse.Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand.Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP).Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates.Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination.Current awareness of piperazines: pharmacology and toxicology.Nephrotoxicity of recreational party drugs.Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.Update on 1-benzylpiperazine (BZP) party pills.Nephrotoxic effects of designer drugs: synthetic is not better!Toxicology and management of novel psychoactive drugs.Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis.In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis.Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography.Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum.Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication.Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release.Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol.

P2860

Q21558551-D8E5519C-C12C-4C19-B82C-034EF0CF6687 Q22251113-C8D7203C-50E1-4E97-A435-8AD2E0451581 Q24619949-FD736735-630D-49CB-AEE3-BEDCF58F45B6 Q24629918-388D70F4-A8AE-460D-B7CE-D391E573CDAE Q24657405-8558BF54-9621-4EA4-B22A-90653E9CAB52 Q28238953-2755A35A-7F40-4495-87D2-0206E5AE383B Q33841160-E00ECF2C-66AC-4B6C-98F4-EC35555DF6D5 Q34100617-CB5539C5-FC17-4C63-9FE7-FC7231250B28 Q34178580-F602BCF1-3DF3-4B1B-8B68-441D8350491D Q34270004-52AB3E8F-32E9-488A-8782-01B1D15A43B1 Q34521098-007C9F8C-CACE-4CF7-8370-89D495F2E053 Q34565712-56750B32-9E1B-455C-A196-C0D63E55EF71 Q34580800-B593B529-D497-4A44-AC8C-8D1154AF03A7 Q34678483-C0CF7C13-6B97-4538-B4ED-76267927972D Q34760266-A150D36B-2668-4536-ABCB-F8EDF706580F Q34839105-1E905DA0-03F8-4283-B38D-EA8B21FE076D Q35032325-E8BB6F3E-D603-48A7-9D56-D9AE673937D0 Q36151338-33D29B54-1937-4725-B883-0A60C89A30FA Q36316039-54DE29CC-DD8B-44E9-9828-9C91E558A878 Q36666580-9A1D4633-460F-47BE-83C4-E7B84AE3A9C0 Q36764292-38178BC8-B4F5-4FA7-A21F-F78A00B62537 Q36800689-8DB7C667-5C5D-4C27-8FE6-C7EB24011AC7 Q37169002-0267AA84-53C5-446F-B7E2-FB5EB9A7AE88 Q37334221-79E2F4BB-F5D8-428B-86C9-C8A5B80BDCFA Q37705731-E8ED47D8-0E62-4926-A0C4-84E0A63D1AF0 Q37871581-3A0C4F69-57FE-4CFE-9BDF-62AC99C4BB6A Q37899848-4E15FBB0-1714-489F-BAA0-576166081844 Q37953950-4BCEB2A1-9FFB-4DC4-9C96-3A679A7D70CD Q38048826-62E556BE-700B-452B-9C2C-F6A17BF94766 Q38107787-49A8E6D5-5DD7-4E41-AC78-E4D6E465132D Q38198873-E014A07B-92DE-4D9E-BA62-E0E9F137E7EA Q38254814-F6F56EB8-D31E-4FF1-AA37-84A9F8D87F99 Q38294121-6798B098-CBA8-4973-BDBA-4C662663A990 Q39643944-0416291B-6C4F-44C3-8DE5-4743B5D7844F Q39690848-2BDE5211-C0E3-4945-A333-FF037DF2C79D Q41040391-BC79F608-6881-44F1-AB5A-63D7460EC301 Q43180903-55BC8343-C9D0-4D7F-BB38-A749B5081DC4 Q43676016-FE136635-456A-4D8C-8496-A2A4AD2908A9 Q44891175-8D7E2070-3EA4-480A-A6BF-18F9044FED12 Q46070387-7DB003E1-A93F-4712-BB7C-551D6C17C620

P2860

N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').

http://www.wikidata.org/entity/Q34360861

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@ast

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@en

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@nl

type

label

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@ast

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@en

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@nl

prefLabel

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@ast

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@en

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@nl

P1433

Q34360861-890CA276-1E23-4A1D-933E-BCF72B5E4B12

P1476

Q34360861-F4EB7D54-AD8B-41D1-9A64-7ADB10078330

P2093

Q34360861-0A39111E-1F89-4F81-928C-4CE314714245

Q34360861-13D1D153-DD9F-445C-BAB6-9B106591BFF3

Q34360861-372C7887-E443-4C5A-97EF-6EDB26B593AE

Q34360861-B65D1ADD-63D0-4812-B2EA-90CA5B10303C

Q34360861-B6CBD4A9-244F-4F56-8241-DFEA5C4D5364

Q34360861-F5778C48-FAFB-4DD4-BAF9-47A870DEBD5E

P2860

Q34360861-03DD6992-5404-4AAA-B9BA-B5C2E0DE4B1E

Q34360861-0DFD4B67-C117-43EA-BB19-A0F109D52B95

Q34360861-10C08518-4F98-464A-87AE-B4DE1ADDBE4A

Q34360861-1F1A7831-A030-4F79-A889-D3D16CC50A76

Q34360861-1F3E39A7-142A-4725-ADE8-2A4385970D67

Q34360861-2FC6A1BB-7BC6-4616-82F5-F7A81D3DEB58

Q34360861-30C47389-EBA3-4F8B-867C-AFCAB2B432E6

Q34360861-3E126408-63CB-4640-8E51-CA0F32FAEE6F

Q34360861-3E78F65E-1F95-4580-92F2-741D0C8604E7

Q34360861-51F288DF-2AB6-4229-9144-56A4549AAA4D

P2888

Q34360861-B3355E68-FB4B-4FB7-88F8-D3FF818065B9

P304

Q34360861-85A84588-74C0-4BE6-A966-C517DE28FEB4

P31

Q34360861-1A3A42CF-3C85-4162-A7A5-BED27407BA48

P356

Q34360861-ED7AD790-8526-4433-997C-4A490ADC8650

P407

Q34360861-F27B8CFB-CCF2-4BB3-8128-1C844EE32DB3

P433

Q34360861-2DD95594-58CC-43B6-B4F6-7595B25FDEAD

P478

Q34360861-7703769A-DECD-4F5A-834D-C0D0BC69DC36

P577

Q34360861-A5B4A5FD-C077-437C-BF31-219E39BB2F18

P5875

Q34360861-0B238462-8ED6-4042-BCBF-592942E963CC

P6179

Q34360861-4A9EF17D-ABE4-4157-B100-875C5E3E6FE7

P698

Q34360861-C4729A26-E9A7-49E9-B94A-AC814D5CE84B

P356

P1433

Neuropsychopharmacology

P1476

N-substituted piperazines abus ...... hetamine (MDMA, or 'Ecstasy').

@en

P2093

Allison G Budzynski

http://www.w3.org/2001/XMLSchema#string

Bruce E Blough

http://www.w3.org/2001/XMLSchema#string

John S Partilla

http://www.w3.org/2001/XMLSchema#string

Michael H Baumann

http://www.w3.org/2001/XMLSchema#string

Richard B Rothman

http://www.w3.org/2001/XMLSchema#string

Robert D Clark

http://www.w3.org/2001/XMLSchema#string

P2860

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine

Serotonin-releasing effects of substituted piperazines in vitro

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats

5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB

MDMA: a review of epidemiologic data.

Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.

Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market.

Ecstasy (MDMA): a review of its possible persistent psychological effects.

5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum.

P2888

P304

550-560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300585

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8220015

http://www.w3.org/2001/XMLSchema#string

P6179

1018441766

http://www.w3.org/2001/XMLSchema#string

P698

15496938

http://www.w3.org/2001/XMLSchema#string